News | Stroke | October 29, 2015

Many Physicians Feel Uninformed About Diagnostic, Treatment Approaches for Cryptogenic Stroke

AHA/ASA conference of experts discusses prevention, diagnosis and treatment for the nearly 200,000 patients who suffer strokes of unknown cause each year

cryptogenic stroke, American Heart Association, American Stroke Association, new survey

October 29, 2015 — Results from a new survey from the American Heart Association/American Stroke Association found that only half of healthcare professionals consider themselves adequately equipped with information about cryptogenic stroke, a stroke in which the underlying cause is still unknown after extensive testing. Depending on their specialty, 51-70 percent of physicians admit being uncertain about the best approaches to finding the underlying causes of these strokes. The survey, conducted in summer 2015, polled 652 healthcare professionals including neurologists, cardiologists, hospitalists, primary care physicians and stroke coordinators.

Leading healthcare providers from across the United States convened Oct. 9 in Washington, D.C., at the Cryptogenic Stroke Public Health Conference to discuss the new survey findings and possibilities for a coordinated, systematic approach to diagnose and manage patients with cryptogenic stroke. The conference was sponsored by the American Heart Association/American Stroke Association with support from Medtronic.

Each year, approximately 200,000 Americans have a stroke that is called cryptogenic because the initial search for its cause is unrevealing, and statistics show that these patients have reason to be concerned: A prior stroke is the No. 1 risk factor for a second stroke, and a second stroke is 16 times more likely to be fatal. If the cause is undiagnosed, it is not possible that the best treatments to prevent a second stroke are being employed.

"The ability to discern the causes of cryptogenic strokes has profound implications for preventing secondary strokes and improving patient outcomes," said Mary Ann Bauman, M.D., chair of the American Stroke Association Advisory Committee. "With the Cryptogenic Stroke Public Health Conference, we are coming together as a healthcare community to increase our knowledge about cryptogenic stroke and improve treatment."  

Importantly, healthcare professionals recognize that among other causes, atrial fibrillation (AF), an irregular heartbeat that may occur only intermittently and thus be difficult to detect, can be a cause of cryptogenic stroke; however, according to the survey, physicians are not always sure how best to detect AF.

AF is one of several possible causes of cryptogenic stroke. Other common causes that should be investigated include patent foramen ovale (PFO) — a hole between the heart's upper chambers — and various forms of blood clotting disorders.

The outcome of the conference was to explore possible common and consistent protocols and pathways to improve quality of care; and to try to develop consensus among healthcare professionals from different specialities to better collaborate on patient treatment.

"We know that collaboration between those who serve cryptogenic stroke patients which is likely to require educating healthcare providers and the scientific community about cryptogenic stroke, appropriate work up, applicable studies and outcomes," Bauman said. "This is important, because stroke is the fifth leading cause of death in the U.S. and a leading cause of severe, long-term disability." 

For more information: www.strokeassociation.org

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp